文献速递产科母胎医学生殖医学

母亲年龄与辅助生殖子代低出生体重和早产风险

Maternal age and risk of low birth weight and premature birth in children conceived through medically assisted reproduction. Evidence from Finnish population registers.
PubMed 文献 · Hum Reprod · 2020-01-01

结果显示,辅助生殖母亲在25—39岁范围内年龄与低出生体重风险无显著关联,仅40岁及以上风险升高;自然受孕母亲则呈明显年龄梯度。

要点

  • 辅助生殖母亲25—39岁生育时低出生体重风险不随年龄增加。
  • 辅助生殖母亲40岁及以上低出生体重风险升高约6个百分点。
  • 自然受孕母亲35岁起低出生体重和早产风险呈明显年龄梯度上升。

核心结论

  • 辅助生殖母亲的不良出生结局风险不随母亲年龄增加而升高,仅40岁及以上例外。
  • 自然受孕母亲中低出生体重和早产风险随年龄呈明显梯度上升。

研究设计与样本

  • 采用线性概率模型比较辅助生殖与自然受孕母亲的年龄梯度,并调整母亲急慢性疾病、家庭收入和孕期吸烟。

主要发现

  • 辅助生殖母亲低出生体重总体发生率为12.6%,25—29岁较30—34岁风险低0.22个百分点(95%CI:-3.2,2.8),35—39岁低1.34个百分点(95%CI:-4.5,1.0)。
  • 辅助生殖母亲40岁及以上低出生体重风险升高6个百分点(95%CI:0.2,12)。
  • 自然受孕母亲低出生体重总体发生率为3.3%,35—39岁较30—34岁风险高1.1个百分点(95%CI:0.6,1.6),40岁及以上高1.5个百分点(95%CI:0.5,2.6)。
  • 早产结果与低出生体重相似。

关键数值与推荐

  • 低出生体重定义为出生体重<2500 g,早产定义为妊娠<37周分娩。
  • 辅助生殖受孕通过国家处方登记中处方药购买记录识别。

临床怎么用

  • 咨询辅助生殖母亲时可告知40岁以下年龄增长不显著增加低出生体重和早产风险。
  • 40岁及以上辅助生殖母亲仍需关注不良出生结局风险。
  • 自然受孕高龄母亲应按常规关注低出生体重和早产风险。

局限性

  • 行政数据限制可纳入的混杂因素数量。
  • 难以依据辅助生殖治疗类型可靠区分母亲。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does the risk of low birth weight and premature birth increase with age among mothers who conceive through medically assisted reproduction (MAR)? SUMMARY ANSWER: Among MAR mothers, the risk of poorer birth outcomes does not increase with maternal age at birth except at very advanced maternal ages (40+). WHAT IS KNOWN ALREADY: The use of MAR treatments has been increasing over the last few decades and is especially diffused among women who conceive at older ages. Although advanced maternal age is a well-known risk factor for adverse birth outcomes in natural pregnancies, only a few studies have directly analysed the maternal age gradient in birth outcomes for MAR mothers. STUDY DESIGN, SIZE, DURATION: The base dataset was a 20% random sample of households with at least one child aged 0-14 at the end of 2000, drawn from the Finnish population register and other administrative registers. This study included children who were born in 1995-2000, because the information on whether a child was conceived through MAR or naturally was available only from 1995 onwards. PARTICIPANTS/MATERIALS, SETTING, METHODS: The outcome measures were whether the child had low birth weight (LBW, <2500 g at birth) and whether the child was delivered preterm (<37 weeks of gestation). Conceptions through MAR were identified by examining data on purchases of prescription medication from the National Prescription Register. Linear probability models were used to analyse and compare the maternal age gradients in birth outcomes of mothers who conceived through MAR or naturally before and after adjustment for maternal characteristics (i.e. whether the mother suffered from acute/chronic conditions before the pregnancy, household income and whether the mother smoked during pregnancy). MAIN RESULTS AND THE ROLE OF CHANCE: A total of 56 026 children, 2624 of whom were conceived through MAR treatments, were included in the study. Among the mothers who used MAR to conceive, maternal age was not associated with an increased risk of LBW (the overall prevalence was 12.6%) at ages 25-39. For example, compared to the risk of LBW at ages 30-34, the risk was 0.22 percentage points lower (95% CI: -3.2, 2.8) at ages 25-29 and was 1.34 percentage points lower (95% CI: -4.5, 1.0) at ages 35-39. The risk of LBW was increased only at maternal ages ≥40 (six percentage points, 95% CI: 0.2, 12). Adjustment for maternal characteristics only marginally attenuated these associations. In contrast, among the mothers who conceived naturally, the results showed a clear age gradient. For example, compared to the risk of LBW (the overall prevalence was 3.3%) at maternal ages 30-34, the risk was 1.1 percentage points higher (95% CI: 0.6, 1.6) at ages 35-39 and was 1.5 percentage points higher (95% CI: 0.5, 2.6) at ages ≥40. The results were similar for preterm births. LIMITATIONS, REASON FOR CAUTION: A limited number of confounders were included in the study because of the administrative nature of the data used. Our ability to reliably distinguish mothers based on MAR treatment type was also limited. WIDER IMPLICATIONS OF THE FINDINGS: This is the first study to analyse the maternal age gradient in the risk of adverse birth outcomes among children conceived through MAR using data from a nationally representative sample and controlling for important maternal health and socio-economic characteristics. This topic is of considerable importance in light of the widespread and increasing use of MAR treatments. STUDY FUNDING/COMPETING INTEREST(S): Funding for this project was provided by the European Research Council (grant no. 803959 MARTE to Alice Goisis and grant no. 336475 COSTPOST to Mikko Myrskylä). E.S. reports personal fees from Theramex, personal fees from Merck Serono, personal fees from Health Reimbursement Arrangement, non-financial support from Merck Serono and grants from Ferring, grants from Theramex, outside the submitted work. The remaining authors have no competing interests. TRIAL REGISTRTION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Barbuscia A, Martikainen P, Myrskylä M, et al. Maternal age and risk of low birth weight and premature birth in children conceived through medically assisted reproduction. Evidence from Finnish population registers. Hum Reprod. 2020. PMID: 31967314. doi:10.1093/humrep/dez275

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。